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Background 
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent skin cancer, with an estimated 
400,000 new cases reported yearly in the United States (1). Although metastasis is relatively uncommon, 
prognosis in patients with lymph node positive cSCC is poor and 5-year survival rates are low (2). 
Furthermore, advanced and often inoperable, loco-regional disease is frequent with cSCC and such 
patients would benefit from effective, targeted chemotherapies.  The hunt for genetic drivers and thus 
potential targets for cSCC therapy is hampered by a mutation burden greater than any other known 
cancer with metastatic potential (3-5), only exceeded by basal cell carcinoma of the skin (S1). Deep 
sequencing of cSCC has identified key driver mutations in tumor suppressor genes (3-5) which are 
difficult to target therapeutically as it is easier to inhibit the action of a protein than it is to replace its 
function when missing. A pathway centric approach may be a more appropriate route for therapy 
development because somatic, cancer-promoting mutations may affect multiple nodes within the same 
pathway leading to downstream activation (6). We recently identified frequent CARD11 mutations in 
cSCC, which lead to aberrant NFkB signalling (7). Nuclear factor kappa-b (NFκB) signaling plays a crucial 
role regulating proliferation and differentiation in the epidermis and alterations can lead to skin 
pathologies with significant burden to human health such as psoriasis and cSCC. One gene reported as 
integral to a number of ubiquitous signaling pathways (including NFκB) is CREBBP which encodes the 
protein CBP, a transcriptional co-factor with lysine acetyltransferase activity and close homology to p300 
(S2). CREBBP loss of function (LOF) mutations are frequently identified in a range of different cancers 
such as lymphomas and carcinomas of the bladder and esophagus (S3-5). 
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3 
Questions Addressed 
We previously identified CREBBP mutation in 35% of 20 cSCC using exome sequencing (4). Here we 
address whether CREBBP mutation is present in a larger cohort of cSCC samples (n=91). 
Experimental Design 
Please see supporting information (Data S1). 
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Results 
To define CREBBP mutation in a larger cohort of human cSCC we used targeted re-sequencing of 91 
samples previously isolated and used to re-sequence potential driver genes such as NOTCH1, TP53 and 
CARD11, as described (4,7). CREBBP mutation frequency was high (33/91 cSCC tumors, 36%, compared 
with 7/20, 35%, in the original exome sequencing cohort). Thus, CREBBP is frequently mutated in human 
cSCC (mutations listed in Supporting Table S1). We next compared the spectrum of CREBBP mutation in 
cSCC with those reported for other tumors in the catalogue of somatic mutations in cancer (COSMIC) 
(S6) and identified that 50/51 cSCC mutations were missense, in contrast to those reported in COSMIC 
(n=758) where >25% of mutations were either non-sense or insertion/ deletion mutations leading to 
frame-shift and a premature termination codon (PTC) (Figure 1A). The majority of such mutations are 
predicted to result in expression of a truncated protein that is either greatly reduced or absent as a 
result of non-sense mediated decay (NMD). Analyzing mutation spectrum by tissue type in COSMIC 
identified certain tumor groups with greater than 33% mutations leading to PTC such as the 
hematopoetic and lymphatic system as well as esophagus. Bladder harboured 75% non-sense or 
insertion/ deletion mutations (Figure 1B). 
Two previous studies support our observations that loss of function mutation in CREBBP is not prevalent 
in primary cSCC; Durinck and colleagues identified 1 missense mutation from 8 cSCC (3), while Pickering 
and colleagues identified 24 mutations in a cohort of 39 aggressive, primary cSCC, 21 of which were 
missense or silent (5). 
Given the spectrum of mutation in cSCC we speculated whether cSCC CREBBP mutation, unlike other 
tumors with a high CREBBP mutation frequency, does not result in CBP loss of function. To address this 
immuno-histochemistry (IH) was used to interrogate the expression level and distribution of CREBBP in 
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5 
normal skin, and cSCC tumors. Using an antibody raised against the C-terminus of CBP nuclear reactivity 
was clearly demonstrated throughout basal and suprabasal layers of normal skin (Figure 2A) and nuclear 
reactivity in all 21 cSCC samples tested was also observed. These data are in line with two different 
antibodies published at The Human Protein Atlas (8) (http://www.proteinatlas.org/ accessed November 
17
th
 2015). In our study, well-differentiated cSCC tumors (n=13) exhibited a pattern of strong positive 
reactivity but loss in central keratinizing areas (Figure 2B). On the other hand, in 8 cSCC samples with 
poorly differentiated regions there was greater variability where regions of weak positivity intermixed 
with negative tumor cells were observed in 3 of 8 high-grade tumours (Figure 2C). 
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Conclusion 
CREBBP is regularly found to be inactivated through loss of function mutations in a range of 
malignancies (S3-5). In contrast we find cSCC harbor missense mutation, and very few mutations that 
predict loss of function. Furthermore, we identify CBP in all 21 cSCC examined, indicating that protein is 
expressed and localizes to the correct compartment.   It is unclear at this time, however, what role CBP 
may have in cSCC, but it is interesting to note that CBP/p300 is critical for efficient removal of UV-
induced pyrimidine dimers (S7). Furthermore, recent genomic analysis of 29 lymph node metastases 
from primary cSCC showed frequent (28%) CREBBP mutation (9) but here the majority of alterations 
(6/8) were truncating or insertion/ deletion mutations predicted to lead to LOF. This result may indicate 
that CBP inactivation is associated with tumor progression in cSCC and agrees with our IH observation, 
also in a limited number of samples, that a degree of CBP loss is observed in high grade tumors (Figure 
2C). However, these observations will need to be confirmed, and the data presented here together with 
the recent finding that, unlike NOTCH1, CREBBP mutation is not frequent or positively selected for in 
normal, sun-exposed skin (10), suggests that CREBBP mutation is unlikely to be an early event in 
squamous cell carcinogenesis. 
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Figure Legends 
Figure 1: CREBBP mutations in cSCC (n=51) are predominantly missense and distribute evenly with the 
exception of the bromo and Creb domains as compared to CREBBP mutation in other tumor types 
(n=785). A: CREBBP mutations (indicated by vertical bars) in cSCC identified in this study (A, upper 
cartoon) compared with COSMIC (A, lower cartoon), a catalogue of somatic mutations in cancer 
(accessed June 5
th
 2015; http://cancer.sanger.ac.uk/cosmic). Fewer nonsense or insertion/ deletion 
mutations (In/Del) are observed in cSCC (upper cartoon) compared with mutations reported in COSMIC 
(lower cartoon). Green = missense, Red = nonsense and Yellow = insertion/ deletion. Vertical bars above 
each CREBBP cartoon indicate two or more mutations present at the same amino acid position; area 
reflects the number of mutations at a given amino acid residue. Orange horizontal bars below cSCC 
CREBBP cartoon indicate two regions of low sequence coverage in our study (2-10 reads). Position of 
protein domains depicted in the CREBBP cartoon is based on NCBI GenPept entry NP_004371, accessed 
June 15
th
 2015. B: Analysis of COSMIC data identifies varying contribution of nonsense and In/Del 
mutation in tumors arising at different body sites. 
Figure 2: Immunohistochemistry using a CBP (C-1) antibody raised against a C-terminal epitope of the 
CREBBP protein detected expression in normal skin (A, top panel) and comparable or increased levels in 
well-differentiated cSCC (n=13) (B, bottom panel shows higher magnification of top panel). 3/8 poorly 
differentiated cSCC exhibited regions of weak positivity intermixed with negative cells (C, bottom panel 
shows higher magnification of top panel). Lower panel in A shows negative control performed on 
duplicate tissue sections by omitting the primary antibody incubation step. Bar = 300µm. 
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Figure 2  
106x48mm (150 x 150 DPI) 
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Data S1. Materials and Methods 
Sequencing 
Sample collection and sequencing was carried out as described previously (South et al 2014). Ethical 
approval for this investigation was obtained from the East London and City Health Authority local ethics 
committee and the study was conducted according to the Declaration of Helsinki Principles. All patients 
participating in this study provided written, informed consent. Punch biopsies of cSCC tissue were taken 
after surgical excision of tumors and immediately snap-frozen in liquid nitrogen with the remainder of 
the tumor sent for formalin fixation and histopathologic diagnosis. For CREBBP amplification, primers 
were designed and validated by Fluidigm (Fluidigm Corporation, San Francisco, CA) per recommended 
guidelines for Roche Titanium sequencing (Roche, Mannheim, Germany). Each primer included sample-
specific Fluidigm 454 barcode primer and adapter sequences. Primer sequences are available on 
request. Reactions contained 50ng genomic DNA, forward and reverse tagged amplification primers 
(1μM), forward and reverse barcode primers (400nM), 1x Access Array Loading Reagent, 1x FastStart 
High Fidelity Reaction Buffer, 4.5mM MgCl2, 5% DMSO, 0.05U FastStart High Fidelity Enzyme Blend and 
PCR-grade nucleotide mix (200μM, Roche). Thermal cycling was performed on the Fluidigm FC1 Cycler 
per manufacturer guidelines. The resultant libraries were harvested and collected on a microtiter plate 
and were normalized and pooled before purification using Agencourt AMPure XP system (Beckman, UK) 
per the manufacturer’s protocol. Library components were clonally amplified using the GSJunior emPCR 
Lib-A Kit (Roche) by inputting 1 molecule of library DNA per capture bead. Pyrosequencing was 
performed using the GS Junior system (Roche/454 Life Sciences). Mapping and variant calling were 
performed as described
5
.  cSCC mutations were compared to those previously reported in COSMIC
6
, an 
online catalogue of mutations in cancer (http://cancer.sanger.ac.uk/cosmic). 
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Immunohistochemistry (IH) 
Immunohistochemical staining was performed on formalin-fixed paraffin-embedded cSCC tissue 
specimens and normal skin specimens. Tissue sections were cut at a thickness of 3 µm onto 3-
aminopropyltrioxysilane-coated slides and dried overnight in a 45
o
C oven followed by de-waxing and 
dehydration in xylene and industrial methylated spirits. Antigen retrieval was performed by incubating 
sections in TRIS-EDTA-citrate antigen unmasking solution (5g EDTA, 2.5g TRIS base and 3.2g sodium 
citrate in 1 litre of distilled water, pH adjusted to 8.1 with sodium hydroxide) for 35 minutes in a 
microwave set to full power. Endogenous peroxidase activity was blocked at ambient temperature in 3% 
hydrogen peroxide in distilled water for 15 minutes (cSCC) or 45 minutes (normal skin). A monoclonal 
antibody against the C-terminus of human CREBBP (CBP (C-1): sc-7300; Santa Cruz Biotechnology Inc, 
Santa Cruz, CA) was applied as primary antibody for 40 minutes at ambient temperature at a dilution of 
1:10. Incubation with secondary biotinylated antibody followed by streptavidin-biotin-peroxidase 
complex was performed using the Vector Elite ABC kit (Vector Laboratories, CA, USA) according to the 
manufacturer’s instructions with diaminobenzidine as the chromogen and haematoxylin as counterstain. 
Negative control reactions were performed on duplicate tissue sections by omitting the primary 
antibody incubation step.
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Supporting Table S1: 454 CREBBP  mutations
DNA was isolated from 91 cSCC samples and CREBBP sequencing was carried out using Fluidigm amplicon based 454 pyrosequencing. Mutations meeting filtering criteria are listed below.
Chr = chromosome, Start and end indicate hg19 position, SNP - variant base, REF = reference base. A, C, G and T indicates nucleotide. TGM denotes moderately differentiated sample, TGP denotes poorly differentiated and TGW denotes well differentiated. Amino acid (aa) change and positon relative to the RefSeq gene NM_004380.
Mutation identified in 2 Samples
chr Start End SNP REF A C G T
No. 
Quality 
Reads
No. 
Variants
% Sample aa change aa pos REF
Codon 
change
chr16 3786729 3786730 A G 6 0 46 0 52 6 12 TGM1 Pro:Leu 1494 C CCC:CTC
chr16 3830822 3830823 A G 7 0 58 0 65 7 11 TGM1 Pro:Leu 578 C CCA:CTA
chr16 3843460 3843461 A G 10 0 25 0 35 10 29 TGM10 Ser:Leu 381 C TCG:TTG
chr16 3820826 3820827 A G 9 0 49 0 58 9 16 TGM12 Pro:Leu 875 C CCT:CTT
chr16 3786669 3786670 T C 0 15 0 6 21 6 29 TGM22 Arg:Gln 1514 G CGG:CAG
chr16 3777819 3777820 A G 7 0 6 0 13 7 54 TGM23 Pro:Ser 2410 C CCC:TCC
chr16 3820754 3820755 A G 16 0 24 0 40 16 40 TGM25 Pro:Leu 899 C CCC:CTC
chr16 3786663 3786664 G A 23 0 4 0 27 4 15 TGM28 Ile:Thr 1516 T ATC:ACC
chr16 3832882 3832883 G A 33 0 4 0 37 4 11 TGM28 Ser:Pro 459 T TCT:CCT
chr16 3777899 3777900 A G 4 0 21 0 25 4 16 TGM3 Pro:Leu 2383 C CCC:CTC
chr16 3860694 3860695 T G 0 0 25 4 29 4 14 TGM30 Pro:His 295 C CCC:CAC
chr16 3777902 3777903 T G 0 0 24 4 28 4 14 TGM6 Ser:Tyr 2382 C TCC:TAC
chr16 3843574 3843575 T C 0 26 0 4 30 4 13 TGM6 Gly:Asp 343 G GGC:GAC
chr16 3831268 3831269 C T 0 4 0 30 34 4 12 TGM7 Thr:Ala 538 A ACA:GCA
chr16 3820698 3820699 T C 0 33 0 4 37 4 11 TGP10 Val:Ile 918 G GTC:ATC
chr16 3779536 3779537 G T 0 0 4 33 37 4 11 TGP13 Lys:Asn 1837 A AAA:AAC
chr16 3779340 3779341 A G 7 0 4 0 11 7 64 TGP15 Pro:Ser 1903 C CCG:TCG
chr16 3819310 3819311 A G 12 0 20 0 32 12 38 TGP17 Pro:Leu 975 C CCC:CTC
chr16 3819311 3819312 A G 12 0 20 0 32 12 38 TGP17 Pro:Ser 975 C CCC:TCC
chr16 3786167 3786168 C T 0 4 0 32 36 4 11 TGP3 Ser:Gly 1533 A AGT:GGT
chr16 3777755 3777756 A G 4 0 10 0 14 4 29 TGP6 Thr:Met 2431 C ACG:ATG
chr16 3828780 3828781 T G 0 0 21 4 25 4 16 TGP6 Leu:Ile 621 C CTA:ATA
chr16 3781373 3781374 T C 0 35 0 6 41 6 15 TGW1 Arg:His 1664 G CGC:CAC
chr16 3790522 3790523 A T 10 0 0 24 34 10 29 TGW13 His:Leu 1337 A CAC:CTC
chr16 3789666 3789667 T C 0 34 0 4 38 4 11 TGW14 Ala:Thr 1398 G GCT:ACT
chr16 3830831 3830832 T C 0 38 0 22 60 22 37 TGW14 Ser:Asn 575 G AGC:AAC
chr16 3830742 3830743 T C 0 37 0 9 46 9 20 TGW16 Val:Met 605 G GTG:ATG
chr16 3819274 3819275 C T 0 6 0 28 34 6 18 TGW18 Gln:Arg 987 A CAG:CGG
chr16 3824676 3824677 A G 4 0 10 0 14 4 29 TGW18 Pro:Ser 726 C CCC:TCC
chr16 3781820 3781821 T C 0 20 0 4 24 4 17 TGW19 Asp:Asn 1616 G GAC:AAC
chr16 3900826 3900827 T C 0 97 0 19 116 19 16 TGW2 Ser:Asn 90 G AGC:AAC
chr16 3794894 3794895 C T 0 8 0 17 25 8 32 TGW21 Arg:Gly 1328 A AGG:GGG
chr16 3828788 3828789 A G 26 0 0 0 26 26 100 TGW21 Pro:Leu 618 C CCC:CTC
chr16 3831219 3831220 A G 7 0 25 0 32 7 22 TGW22 Ser:Phe 554 C TCC:TTC
chr16 3860623 3860624 T C 0 24 0 13 37 13 35 TGW22 Val:Ile 319 G GTC:ATC
chr16 3786091 3786092 C T 0 8 0 29 37 8 22 TGW27 Gln:Arg 1558 A CAA:CGA
chr16 3794894 3794895 C T 1 3 0 12 16 4 25 TGW29 Arg:Gly 1328 A AGG:GGG
chr16 3777719 3777720 C T 0 5 0 43 48 5 10 TGW3 Stop:Trp 2443 A TAG:TGG
chr16 3827637 3827638 T C 0 45 0 10 55 10 18 TGW3 Val:Met 712 G GTG:ATG
chr16 3788650 3788651 T C 0 18 0 4 22 4 18 TGW31 Asp:Asn 1435 G GAT:AAT
chr16 3820883 3820884 A G 4 0 25 0 29 4 14 TGW31 Thr:Ile 856 C ACA:ATA
chr16 3900382 3900383 G A 43 0 5 0 48 5 10 TGW4 Val:Ala 238 T GTG:GCG
chr16 3781197 3781198 G A 32 0 4 0 36 4 11 TGW5 Cys:Arg 1723 T TGC:CGC
chr16 3786163 3786164 A G 5 0 16 0 21 5 24 TGW6 Ala:Val 1534 C GCC:GTC
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DNA was isolated from 91 cSCC samples and CREBBP sequencing was carried out using Fluidigm amplicon based 454 pyrosequencing. Mutations meeting filtering criteria are listed below.
Chr = chromosome, Start and end indicate hg19 position, SNP - variant base, REF = reference base. A, C, G and T indicates nucleotide. TGM denotes moderately differentiated sample, TGP denotes poorly differentiated and TGW denotes well differentiated. Amino acid (aa) change and positon relative to the RefSeq gene NM_004380.
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